Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.

Pharmacogenetics and genomics - 1 Apr 2013

van Huis-Tanja Lieke H, Gelderblom Hans, Punt Cornelis J A, Guchelaar Henk-Jan

Abstract excerpt

OBJECTIVE: The availability of current chemotherapeutic options for metastatic colorectal cancer (mCRC) has increased survival, but it is also accompanied by considerable morbidity. Fluoropyrimidines are the mainstay of systemic therapy. Germline pharmacogenetic markers involved in 5-fluorouracil pharmacodynamics could provide individualized pretreatment tools for predicting toxicity. Research on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Deoxycytidine

Share to Drug-Related Side Effects and Adverse Reactions

Share to Fluorouracil

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 23407049
DOI: 10.1097/FPC.0b013e32835ee8e1

Genes

MTHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.PMID 23407049Read ↗

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.Semantic proximity Read ↗

Association of C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer.Semantic proximity Read ↗

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.Semantic proximity Read ↗

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patientsSemantic proximity Read ↗

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Semantic proximity Read ↗

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer PatientsSemantic proximity Read ↗

Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study.Semantic proximity Read ↗

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.Semantic proximity Read ↗

Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.Semantic proximity Read ↗

C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.